realistic. For these secondary rates, both regimens had outcomes similar to those recorded in other studies. Another difficulty with the 12-week endpoint is the very low 33% response of patients with C. glabrata to either regimen. Is this worse than infection with other species of Candida? I do not know.

To end at the beginning: is voriconazole effective and safe in treatment of candidaemia in a general hospital population? Yes. But will it be extensively used? With generic fluconazole for the less seriously ill, and with almost non-toxic echinocandins for the more seriously ill, I see relatively little use for voriconazole in the general hospital setting. In patients with cancer and in some with solid-organ transplants, the major population where voriconazole is likely to be used for its coverage of mycoses caused by filamentous fungi, Kullberg and colleagues’ study gives some comfort for added coverage against fluconazole-susceptible Candida spp. But this same group of patients may have been heavily pre-exposed to fluconazole, and some patients may have refractory C. glabrata or even C. albicans. For these patients I fear that any triazole might have limited value. Pending additional data, I would consider voriconazole a modest addition to our alternatives for treatment of candidaemia.

John R Graybill
Division of Infectious Diseases, University of Texas Health Science Center, San Antonio, TX 78229, USA
graybill@uthscsa.edu
I have received research funding from Merck, Pfizer, Schering, Indevus, Astellas, and Victrion. I have been part of speaker’s bureaux for Merck and Schering, and advisory boards for Merck, Schering, and Victrion.


BCG: the story continues

More people worldwide have been vaccinated with bacillus Calmette-Gueulin (BCG) than with any other vaccine, but its mechanisms of protection against tuberculosis remain largely unknown. In today’s Lancet, Ahmet Soysal and colleagues add a new element to the debate, reporting that, in a population of children who were in close contact with infectious cases of tuberculosis in Istanbul, BCG protects against infection with Mycobacterium tuberculosis. Using a newly developed ELISpot assay measuring the interferon-γ response to specific M tuberculosis antigens as a marker of infection, these authors report that infection with M tuberculosis was more likely to be detected in children without a BCG scar than in those with such a scar. This ambitious study addresses a question that has been central to tuberculosis control for decades: namely, how effective is BCG, and to what extent does it protect against infection or disease?

BCG, the oldest vaccine still in use in the world today, was derived between 1906 and 1919 by in-vitro attenuation of an isolate of M bovis, and was first used as an antituberculosis vaccine in humans in 1921. The question of its protective efficacy against tuberculosis has been raised for several decades, and evidence from several randomised controlled trials and observational studies showed that, in adults, efficacy varied greatly in different populations, from 0 to 80%. The commonest explanation for the variability in BCG vaccine’s protective efficacy is the difference between populations in terms of exposure to cross-reacting environmental mycobacteria, which can either mask or inhibit the protection induced by BCG. In children, however, the protection from BCG appears to be better, especially against the most severe disseminated forms of the disease (miliary tuberculosis and meningitis). This finding has justified the recommendation by WHO that infants should be vaccinated as soon after birth as possible with a single intradermal dose of BCG in countries with a high risk of tuberculosis infection. The standard test for tuberculosis in the absence of...
significant disease was, until recently, the tuberculin skin test, which measures the reaction to intradermal injection of purified protein derivative (PPD). However, because this test lacks specificity due to the presence of antigens shared among most mycobacteria (including BCG), it has never been clear whether BCG vaccination prevents M tuberculosis infection as distinct from clinical disease.

The immunodiagnostic test used by Soysal and colleagues is based on two antigens of M tuberculosis, ESAT-6 and CFP10, which are deleted in all strains of BCG presumably due to the attenuation process. This test is therefore not confounded by BCG vaccination and there is substantial evidence to suggest that immune response to these antigens is a sign of M tuberculosis infection. The authors found that many children who would have been scored as positive in the tuberculin skin test are negative in the ELISpot test. Given that the ELISpot test has repeatedly been shown to be at least as positive as the tuberculin skin test, and considerably more specific, this finding suggests that the discordant results are due to false positive results to the tuberculin skin test. More interestingly, these discordant results (tuberculin skin test positive, ELISpot negative) are strongly associated with BCG vaccination. This finding is consistent with previous studies, which showed that the tuberculin skin test can be confounded by recent BCG vaccination.

On the basis of autopsy studies in Finland in 1979, Sutherland and Lindgren stated that there was no evidence to support the suggestion that, in human beings, BCG vaccine could prevent the establishment of M tuberculosis infection in an exposed person. According to Sutherland and Lindgren, BCG acted by limiting the multiplication and dissemination of the bacilli and the development of lesions after infection. More recently, studies in neonates in The Gambia showed that BCG vaccination induced potent Th1-type immune responses, associated with "adult-like" production of interferon-γ by CD4+ lymphocytes. The use of an interferon-γ assay in BCG-vaccinated infants could then be a marker of vaccine-induced immunity and not of tuberculosis infection. The absence of a response would thus reflect a lack of immunity rather than an absence of infection.

The question is of importance and is more than just an academic debate. If BCG does protect against the development of disease given infection (which has been shown to be of variable efficacy), public-health strategies should focus on finding and treating latent infection as early as possible. However, if instead BCG gives some protection against M tuberculosis infection, the implication is that effort can most usefully be expended on preventing new infections in early adulthood. In view of the points above, the study by Soysal and colleagues does not provide a definitive answer. Their work highlights the difficulties inherent in the study of tuberculosis, where distinguishing between latent asymptomatic infection and exposure to infection has proved extremely difficult. One of the reasons for this difficulty might be that the degree of positivity to ESAT-6 (and presumably CFP10 or other antigens) is affected by the degree of exposure and hence the degree of infection.

The use of an interferon-γ assay in BCG-vaccinated infants could then be a marker of vaccine-induced immunity and not of tuberculosis infection. The absence of a response would thus reflect a lack of immunity rather than an absence of infection.

### Rights

Rights were not granted to include this image in electronic media. Please refer to the printed journal.
Reorienting health-research communication

Much commentary and exhortation focuses on getting research evidence into health policy and practice. Bowen and Zwi\(^1\) advocated that strategies to promote evidence-informed policy and practice should be built on theory and empirical evidence, and take into account the interactive and changing relations between science and society. Unfortunately, these considerations are often disregarded when health research is communicated.

Using evidence to guide action is a central tenet of health researchers, but apparently not when they communicate their findings. Eccles et al\(^2\) reviewed 235 evaluations of guideline dissemination and implementation strategies over 25 years and found that, “few authors gave any rationale for their choice of interventions and presumably used their common sense to choose the interventions.” The absence of a strong empirical and theoretical base for health-research communication risks duplication of efforts and ineffective strategies, hinders evaluation and learning, and provides little guidance for further research, policy, and practice.\(^3,4\)

Yet, communication and policy studies, and the philosophy and sociology of science, have long focused on the complex relations and multidirectional influences between science, state, and wider society.\(^4\) Health-research communication would benefit greatly from drawing more consistently on this multidisciplinary base.

Like their religious forebears, the “high priests” of medical research and other health sciences typically issue “messages” as if these should unquestioningly be accepted and society transformed as a result. Lord Winston, an eminent UK scientist, called for a re-orienting of health-research communication.\(^5\) There is also scepticism about authoritative claims and the “truthfulness” of scientific messages, in part, simply because orthodoxies are periodically overturned.\(^6\) For example, a contemporary randomised trial indicated that the widely accepted use of corticosteroids to treat head injuries could be harmful.\(^7\) He cited the drop in infant immunisation rates after the measles-mumps-rubella vaccine controversy as one example of research communication failures and of declining social trust in science.

For example, a contemporary randomised trial indicated that the widely accepted use of corticosteroids to treat head injuries could be harmful.\(^7\) He cited the drop in infant immunisation rates after the measles-mumps-rubella vaccine controversy as one example of research communication failures and of declining social trust in science.